| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000032221 |
| Receipt No. | R000036743 |
| Scientific Title | A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction |
| Date of disclosure of the study information | 2018/04/17 |
| Last modified on | 2020/10/13 (Ver. 8) |
| Basic information | ||
| Public title | A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction | |
| Acronym | A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction | |
| Scientific Title | A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction | |
| Scientific Title:Acronym | A study on the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction | |
| Region |
|
|
| Condition | ||
| Condition | The patients with cancer located at the upper third of the stomach or at around the esophagogastric junction who underwent various types of gastrectomy | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the optimal gastrectomy procedures to improve postoperative QOL for the cancer located at the upper third of the stomach or at around the esophagogastric junction. |
| Basic objectives2 | Others |
| Basic objectives -Others | To study the effect of various surgical procedures and clinical factors on postoperative QOL in each type of gastrectomy. |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The main outcome measures of PGSAS-45 and change in body weight are compared among the different type of gastrectomy for the cancer located at the upper third of the stomach or at the around the esophagogastric junction. |
| Key secondary outcomes | The effects of the surgical procedures and the clinical factors on postoperative QOL are studied in each type of gastrectomy. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) The patients with cancer located at the upper third of the stomach or at around the esophagogastric junction (with any stage or histologic type).
(2) Achieved R0 resection. (3) Without any recurrence or metastasis. (4) The patients who were more than 6 months after gastrectomy. (5) Allowable of former chemotherapy if more than 6 months past after the termination of the treatment. (6) The patients who underwent gastrectomy only once. (7) Performance status 0 or 1. (8) Capable to understand the questionnaire. (9) Without any other disease or previous surgery which may influence the results of questionnaire more than gastrectomy. (10) Without any organ failure or mental disease. (11) Spontaneous agreement of the said person. |
|||
| Key exclusion criteria | (1) Active dual malignancy.
(2) Synchronous another surgery with exception of the resection or the extraction of the perigastric organs to accomplish gastrectomy or lymph node dissection, and ones equivalent to cholecystectomy. (3) Judged as irrelevant by the responsible doctor of this study. |
|||
| Target sample size | 4000 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | The Jikei University Daisan Hospital | ||||||
| Division name | Department of Laboratory Medicine | ||||||
| Zip code | 201-8601 | ||||||
| Address | 4-11-1, Izumihoncyo, Komae-shi, Tokyo, 201-8601 Japan | ||||||
| TEL | 03-3480-1151 | ||||||
| nakada@jikei.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | The Jikei University Daisan Hospital | ||||||
| Division name | Department of Laboratory Medicine | ||||||
| Zip code | 201-8601 | ||||||
| Address | 4-11-1, Izumihoncyo, Komae-shi, Tokyo, 201-8601 Japan | ||||||
| TEL | 03-3480-1151 | ||||||
| Homepage URL | |||||||
| nakada@jikei.ac.jp | |||||||
| Sponsor | |
| Institute | Japan Postgastrectomy Syndrome Working Party
Japanese Society for Gastro-surgical Pathophysiology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Self-funding |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Ethics Committee, The Jikei University School of Medicine |
| Address | 3-25-8,Nishishimbashi, Minato-ku, Tokyo, 105-8461 Japan |
| Tel | 03-3433-1111 |
| rinri@jikei.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東京慈恵会医科大学附属第三病院(東京都)、佐久市立国保浅間総合病院(長野県)、横浜市立市民病院消化器外科(神奈川県)、金沢医科大学(石川県)、国際医療福祉大学病院(栃木県)、今村総合病院(鹿児島県)、名古屋大学(愛知県)、東京大学(東京都)、横浜市立大学附属市民総合医療センター(神奈川県)、岐阜大学(岐阜県)、四国がんセンター(愛媛県)、新潟県立がんセンター新潟病院(新潟県)、がん研有明病院(東京都)、県立広島病院(広島県)、東京慈恵会医科大学附属病院(東京都)、 公立みつぎ総合病院(広島県)、順天堂大学(東京都)、函館五稜郭病院(北海道)、静岡県立静岡がんセンター(静岡県)、滋賀医科大学(滋賀県)、山形県立中央病院(山形県)、島根大学(島根県)、千葉県がんセンター(千葉県)、獨協医科大学(栃木県)、東邦大学医療センター大橋病院(東京都)、愛知県がんセンター中央病院(愛知県)、済生会川内病院(鹿児島県)、大阪医科大学(大阪府)、城山病院(大阪府)、京都府立医科大学(京都府)、大阪府済生会野江病院(大阪府)、堺市立総合医療センター(大阪府)、山梨大学(山梨県)、高知大学(高知県)、札幌医科大学(北海道)、鹿児島大学(鹿児島県)、大阪市立大学(大阪府)、勤医協中央病院(北海道)、呉医療センター・中国がんセンター(広島県)、東京医科大学(東京都)、おおもと病院(岡山県)、帝京大学(東京都)、箕面市立病院(大阪府)、前橋赤十字病院(群馬県)、石川県立中央病院(石川県)、南大阪病院(大阪府)、聖路加国際病院(東京都)、日赤和歌山医療センター(和歌山県)、大分県厚生連鶴見病院(大分県)、富山県立中央病院(富山県)、奈良県立医科大学(奈良県)、JA広島総合病院(広島県)、青森県立中央病院(青森県)、聖マリアンナ医科大学(神奈川県)、山口大学(山口県)、千葉大学(千葉県)、広島市立安佐市民病院(広島県)、 国立がん研究センター中央病院(東京都)、久留米大学(福岡県)、京都医療センター(京都府)、岐阜市民病院(岐阜県)、立川メディカルセンター(東京都)、北海道消化器科病院(北海道)、秋田厚生医療センター(秋田県)、大分大学(大分県)、鳥取大学(鳥取県)、名古屋市立大学(愛知県)、北野病院(大阪府)、大津市民病院(滋賀県)、京都大学(京都府)、広島市立広島市民病院(広島県)、広島大学(広島県)、熊本大学(熊本県)、岩手医科大学(岩手県)、栃木県立がんセンター(栃木県)、神戸大学(兵庫県)、仙台医療センター(宮城県)、長岡中央綜合病院(新潟県)、鈴鹿中央総合病院(三重県)、関西医科大学附属病院(大阪府)、宮城県立がんセンター(宮城県)、埼玉医科大学総合医療センター(埼玉県)、福山市民病院(広島県)、東海大学医学部付属八王子病院(東京都)、りんくう総合医療センター(大阪府)、九州大学(福岡県)、筑波大学(茨城県)、八尾市立病院(大阪府)、神奈川県立がんセンター(神奈川県)、関西労災病院(兵庫県)、弘前大学(青森県)、昭和大学藤が丘病院(神奈川県)、東海大学(神奈川県)、鳥取県立中央病院(鳥取県)、佐世保市総合医療センター(長崎県)、慶應義塾大学(東京都)、大阪急性期・総合医療センター(大阪府)、広島記念病院外科(広島県)、生麦病院(神奈川県)、佐久医療センター(長野県)、JCHO札幌北辰病院(北海道)、福岡大学病院(福岡県)、埼玉医科大学国際医療センター(埼玉県)、北里大学北里研究所病院(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 1909 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | (1) Date of birth, gastrectomy and entry in the questionnaire
(2) Sex (3) Height, body weight (at just before gastrectomy and at entry in the questionnaire) (4) Pathological stage, histological type, location of the cancer (5) Presence or absence of either neoadjuvant or adjuvant chemotherapy, regimens (6) The level of esophago-gastric or esophago-jejunal anastomosis (7) Type of gastrectomy and reconstruction method And so on |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000036743 |